DeMartini A L, Buzdar A U, Blumenschein G R
J Surg Oncol. 1983 May;23(1):32-4. doi: 10.1002/jso.2930230109.
Included in this study were 43 breast cancer patients treated with adjuvant chemotherapy who presented metastasis only in bone. Forty-two percent had metastasis during chemotherapy, and 58% had metastasis after the completion of chemotherapy. In 66% of the patients, the lesions were osteolytic. Twenty-nine percent had osteoblastic lesions, and 5% had mixed lesions. Of the patients with osteoblastic metastatic disease, five showed asymptomatic, osteoblastic disease; this response was considered to be a healing response to chemotherapy. These five patients were continued on the same therapy. The median duration of this response to the adjuvant chemotherapy was 29 months (range 6 to 62+). In one patient, osteoblastic disease gradually faded, and skeletal radiographs reverted to normal.
本研究纳入了43例仅发生骨转移的接受辅助化疗的乳腺癌患者。42%的患者在化疗期间发生转移，58%的患者在化疗完成后发生转移。66%的患者病变为溶骨性。29%的患者有成骨性病变，5%的患者有混合性病变。在有成骨性转移疾病的患者中，5例表现为无症状的成骨性疾病；这种反应被认为是对化疗的愈合反应。这5例患者继续接受相同的治疗。辅助化疗这种反应的中位持续时间为29个月（范围6至62+）。在1例患者中，成骨性疾病逐渐消退，骨骼X线片恢复正常。
